B+
Bull case
20%
Probability
Target price
$19.00
+185.7% vs current
EPRX
EupraxiaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$13.35
+100.8% vs current
B-
Bear case
20%
Probability
Target price
$8.56
+28.7% vs current
AI sentiment snapshot
Latest data as of 2026-02-19
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Sentiment is cautiously constructive. The analyst median (base_target $13.345) sits materially above the anchor (7.7), indicating tangible upside; the analyst high (19.0) captures optimistic, binary-outcome upside. Near-term tone is tempered by the recent equity offering and financing/dilution risk, so expect elevated volatility around clinical updates and partnering signals. Our view balances upside from execution against material downside if key catalysts disappoint.
RankAlpha Sentiment AI - 2026-02-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20catalystAnalyst 12-month consensus targetsHigh impact
Published analyst consensus (median ~ $13.00–$14.00) implies material upside vs the anchor; sources summarized from market consensus [#SERP-3], [#SERP-1].
2027-02-19eventClinical readout / regulatory milestone (assumed window end)High impact
No firm public readout date disclosed; conservatively assume window end used for planning (assumption noted) — material binary outcome could move shares materially.
2027-02-19catalystPartnership / commercial progressHigh impact
Potential licensing or commercial deals over the next 12 months could re-rate valuation if achieved; timing uncertain, treated as long catalyst.
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-19 • Updated nightlySource: Internal modelMethodology